AbbVie Inc. $ABBV Shares Bought by Legacy Trust

Legacy Trust boosted its stake in AbbVie Inc. (NYSE:ABBV) by 186.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,042 shares of the company’s stock after buying an additional 4,583 shares during the period. Legacy Trust’s holdings in AbbVie were worth $1,631,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Philip James Wealth Mangement LLC bought a new position in shares of AbbVie in the third quarter valued at approximately $205,000. ORG Wealth Partners LLC grew its holdings in shares of AbbVie by 14.0% in the 3rd quarter. ORG Wealth Partners LLC now owns 22,082 shares of the company’s stock worth $5,119,000 after acquiring an additional 2,708 shares during the last quarter. Stonehearth Capital Management LLC acquired a new position in shares of AbbVie in the third quarter worth about $213,000. Steele Capital Management Inc. grew its position in AbbVie by 2.3% during the 3rd quarter. Steele Capital Management Inc. now owns 13,180 shares of the company’s stock worth $3,052,000 after purchasing an additional 300 shares in the last quarter. Finally, Hidden Cove Wealth Management LLC boosted its position in shares of AbbVie by 38.3% in the third quarter. Hidden Cove Wealth Management LLC now owns 1,906 shares of the company’s stock worth $441,000 after buying an additional 528 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research note on Tuesday, November 4th. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Scotiabank started coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target on the stock. Finally, Evercore ISI raised their price target on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $246.89.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple clinical and pipeline updates point to ongoing product-cycle growth (Phase 1 ABBV‑243 safety data, progress on icalcaprant, and completed real‑world studies for Rinvoq and upadacitinib), supporting longer‑term revenue diversification away from Humira. ABBV‑243 Phase 1 Trial
• Positive Sentiment: Zacks and other analysts highlight immunology momentum — strong Skyrizi and Rinvoq demand is expected to help offset Humira LOE, which is a constructive revenue thesis for FY‑2025/2026. Zacks: Immunology expectations
• Positive Sentiment: Dividend-focused coverage (Seeking Alpha pieces) and a recent buy rating from Berenberg support income‑oriented and value investors who view ABBV’s payout and yield as a stabilizer. Seeking Alpha: Dividend thesis Berenberg buy
• Neutral Sentiment: Press swirl about potential suitors for Revolution Medicines (reports that Merck may be in talks) creates market noise that can influence sector comps and M&A speculation but does not change AbbVie’s fundamentals unless a deal is announced. FT: Merck talks on Revolution
• Negative Sentiment: AbbVie publicly denied reports it was in talks to acquire Revolution Medicines after earlier speculation drove gains in both names; the denial removed the takeover premium and likely triggered short‑term selling pressure. Barron’s: AbbVie denies talks
• Negative Sentiment: Management’s updated Q4 and FY‑2025 EPS guidance came in at the low end or slightly below consensus (Q4: 3.320–3.360 vs. cons. 3.360; FY: 10.610–10.650 vs. cons. 10.650), which can cap near‑term upside and weigh on sentiment. (Company guidance update)
• Negative Sentiment: AbbVie flagged IPR&D and related expenses that will negatively impact Q4 EPS, a known near‑term earnings headwind highlighted by Seeking Alpha coverage. Seeking Alpha: IPR&D Q4 EPS impact

AbbVie Stock Down 1.8%

Shares of AbbVie stock opened at $220.06 on Friday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The stock has a market capitalization of $388.93 billion, a P/E ratio of 166.71, a PEG ratio of 0.92 and a beta of 0.36. The stock has a 50 day moving average price of $226.59 and a two-hundred day moving average price of $215.32.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the previous year, the company earned $3.00 earnings per share. AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.